Top Markets
#1 CyberDEX CyberDEX +391.94%
#2 OVERTAKE OVERTAKE +60.20%
#3 deBridge deBridge +25.79%
#4 Clearpool Clearpool +25.70%
#5 Playnance Playnance +23.95%
#6 Nillion Nillion +21.37%
#7 B3 (Base) B3 (Base) +19.47%
#8 AUKI AUKI +15.74%
#9 龙虾 (Lobster) 龙虾 (Lobster) +15.62%
#10 Codatta Codatta +15.06%
Coin of the day
CyberDEX CyberDEX
Settings
Language
ENGLISH
Currency
USD
Theme
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rank in Stocks #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Share Price
$0.00185055
Market Cap
$48.29K
Change (1 day)
-3.55%
Change (1 year)
30.31%
Country
GB
Trade Nuformix plc (NFX)

Category

Healthcare
P/B ratio for Nuformix plc (NFX)
P/B ratio as of September 2026 TTM: 2.01
According to Nuformix plc latest financial reports and stock price the company's current price-to-book ratio (TTM) is 2.01. At the end of 2024 the company had a P/B ratio of 0.64.
P/B ratio history for Nuformix plc from 2014 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 2.01 -61.14%
2025 5.17 703.62%
2024 0.64 44.29%
2023 0.45 -63.79%
2022 1.23 -46.40%
2021 2.30 -42.90%
2020 4.02 28.15%
2019 3.14 93.67%
2018 1.62 -108.69%
2017 -18.66 -793.31%
2016 2.69 0.00%
2014 0.00 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5144 224.23%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.5918 327.62%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9974 98.95%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3983 268.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH